Nidrazid (Isoniazid)

Isoniazid is a pro‑drug that is activated inside Mycobacterium tuberculosis by the bacterial enzyme KatG. The activated form blocks the synthesis of mycolic acids, essential lipids of the bacterial cell wall, leading to loss of cell wall integrity and bacterial death, especially in actively replicating organisms.

The specific dose of isoniazid is determined by the prescribing clinician based on the patient’s age, weight, disease severity, and treatment protocol. Standard adult regimens often involve daily dosing, but the exact amount and duration must be individualized by a qualified healthcare professional.

Isoniazid is classified as pregnancy category unknown, and its safety profile has not been fully established. Use during pregnancy or lactation should be considered only when the potential benefits outweigh the risks, and it should be prescribed under close medical supervision.

To order Nidrazid, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoniazid is often paired with rifampicin, ethambutol and pyrazinamide in first‑line TB therapy. Compared with rifampicin, isoniazid has a narrower spectrum but is highly effective against replicating bacilli and is the drug of choice for latent TB prophylaxis, whereas rifampicin offers broader activity and a different resistance profile.

Nidrazid tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain potency.

Nidrazid is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse effects include hepatotoxicity, which may present as jaundice or elevated liver enzymes, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Peripheral neuropathy can also occur, especially in individuals with poor nutritional status, and may require pyridoxine supplementation.

Isoniazid is contraindicated in patients with known hypersensitivity to the drug, severe liver disease, or documented glucose‑6‑phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis. Caution is also advised for individuals with pre‑existing neuropathy or those taking medications that may interact adversely.